Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245115 · ClinicalTrials.gov registry record · Phase 1
Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT00245115 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 7 participants.
The verdict
NCT00245115, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected. Treating stem cells collected from the patient's blood or bone marrow with chemotherapy in the laboratory removes any remaining cancer cells. Chemotherapy or radiation therapy is given to the patient to prepare the bone marrow for stem cell transplant. The treated stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. PURPOSE: This clinical trial is studying how well an autologous peripheral stem cell or bone marrow transplant using laboratory-treated cells works in treating patients with acute leukemia.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG busulfan
- PROCEDURE in vitro-treated peripheral blood stem cell transplantation
- PROCEDURE in vitro-treated bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-10 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245115
The ClinicalTrials.gov registry entry for NCT00245115 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00245115 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245115 about?
NCT00245115 is a clinical study titled "Ex Vivo Expansion of Mafosfamide Purged CD34+ Cells in Patients With Acute Leukemia". RATIONALE: Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected. Treating stem cells collected from the patient's blood or bone marrow with chemotherapy in the laboratory removes any remaini...
What is the current status of trial NCT00245115?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2005-10. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00245115?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), busulfan (DRUG), in vitro-treated peripheral blood stem cell transplantation (PROCEDURE), in vitro-treated bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00245115?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.